Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study

This multicenter, randomized, controlled, open-label, prospective clinical trial was designed to evaluate the efficacy and safety of doxorubicin hydrochloride liposome injection in combination with irinotican (AI regimen) versus VIT regimen in the treatment of relapsed and refractory pediatric rhabdomyosarcoma.

Trial Details

NCT ID
NCT05457829
Phase
PHASE2
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Rhabdomyosarcoma Sarcoma
Interventions
  • Doxorubicin Hydrochloride Liposome+Irinotecan
  • Temozolomide+Irinotecan+Vincristine
Locations (sample)
  • Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

  • 6 months ≤age≤18 years, no gender limitation;
  • The Karnofsky (≥16 years old) or Lansky (\< 16 years old) physical status score is at least 50;
  • The expected survival time is not less than 12 weeks;
  • Heart function: A) Cardiac COLOR ultrasound detection LVEF≥ 50%; B) EKG suggests no myocardial ischemia;C) No history of arrhythmia requiring drug …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Rhabdomyosarcoma Sarcoma Trials on Trialify →